Cynosure Lutronic is expanding the global market for its high-frequency medical device, XERF, by hosting conferences for healthcare professionals in North America and Europe.
The company announced on Monday that it recently held conferences in the U.S. and Spain to share XERF’s clinical outcomes and treatment techniques.
The Cynosure Lutronic Academy in San Diego drew over 530 attendees from 245 medical institutions across Korea and North America. It also featured the inaugural XERF Masterclass, a specialized training program for North American practitioners.
At the event, U.S. dermatologist Dr. Makrin Alexiadis presented XERF’s clinical results. Dr. Lee Do-young from Hill House Dermatology in Korea introduced a combination treatment strategy incorporating energy-based devices and skin boosters, addressing the theme Defining K-Beauty Standards.
Barcelona, Spain hosted the EMEA Laser and Science Symposium 2026, attracting over 300 healthcare professionals from Europe, the Middle East, and Africa. The symposium also marked XERF’s official European launch.
XERF recently surpassed 3,000 units in global cumulative sales, indicating its expanding presence in key international markets.
The company has strengthened its position for European market entry by securing certification under the European Medical Device Regulation (EU MDR).
Cynosure Lutronic, formed in 2024 through the merger of U.S.-based Cynosure and Korea’s Lutronic, is a global leader in aesthetic medical devices.
Beyond XERF, the company’s portfolio includes a range of energy-based medical devices such as DermaV, Clarity II, and PicoSure Pro.
The European event featured discussions on XERF treatments for patients using GLP-1 obesity medications and insights from local patient demand surveys. Dr. Soo-il Jeon from Jeon Soo-il Dermatology in Korea shared treatment protocols as a guest speaker.
A Cynosure Lutronic spokesperson stated that with this European launch, XERF has now entered major global markets across North America, Asia-Pacific, and Europe-Middle East. It plans to enhance the clinical training programs to address region-specific patient characteristics and treatment trends.